Quantcast

Latest Actinic keratosis Stories

2010-08-06 11:01:00

WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(Nasdaq: DUSA) reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration (FDA) notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan(®) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the prevention of cutaneous squamous cell carcinomas (SCCs) in patients who have a proven history of multiple...

2010-08-05 08:00:00

HAYWARD, Calif., Aug. 5 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser...

2010-07-29 05:30:00

WILMINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its second quarter corporate highlights and financial results press release will be issued on Tuesday, August 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, August 3rd - 8:30 a.m. E.D.T. If calling from North America use the following toll-free number: 800-647-4314...

2010-06-24 05:30:00

All Claims Upheld at Conclusion of Successful Reexamination Process WILMINGTON, Mass., June 24 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and...

2010-05-07 05:30:00

WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U(®), Blue Light Photodynamic Therapy Illuminator. The new patent will have...

2010-05-06 05:30:00

WILMINGTON, Mass., May 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and first quarter financial results press release will be issued on Tuesday, May 11(th) at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, May 11(th) - 8:30 a.m. E.T. If calling from North America use the following toll-free number: 800-647-4314 International callers use: 502-719-4466 Password - DUSA A replay of the call will be...

2010-05-04 07:30:00

WILMINGTON, Mass., May 4 /PRNewswire/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA) is proud to be a supporting sponsor of The Skin Cancer Foundation's annual Road to Healthy Skin Tour for the second consecutive year. The Tour offers free full-body skin exams by physicians and provides informational materials to raise awareness about the importance of early detection, prevention and treatment of skin cancer and precancerous growths such as actinic keratoses (AKs)....

2010-04-29 07:59:00

MONACO, April 29, 2010 /PRNewswire/ -- At the 10th Congress of the European Society for Photodynamic Therapy (Euro PDT), held in Monaco on March 12-13, 2010, Professor Lasse Braathen (Tromso, Norway), president of the Euro PDT, described the current state of topical photodynamic therapy, a revolutionary treatment for precancerous skin lesions and superficial skin carcinomas. He also underscored the major role played by the Euro PDT, whose objective is to promote research, development, and...

2010-04-15 08:00:00

HAYWARD, Calif., April 15 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, today announced the new Fraxel re:store® DUAL laser system for the treatment of actinic keratoses (AK) - a precancerous skin condition caused by sun exposure. As the leader in fractional laser technology,...

2010-03-26 14:29:00

BRISTOL, Tenn., March 26 /PRNewswire/ -- Graceway® Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara(TM), determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK). The new treatment can be used on large areas of skin, including the full face or balding scalp on a convenient, 6-week dosing cycle. Zyclara shares the same...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related